AR and metastatic prostate carcinoma: Ku et al. [58] examined the effects of RB1 and TP53 deletion in a mouse model of metastatic prostate cancer (PTEN loss) and found that EZH2 inhibition restored enzalutamide responsiveness in RB1- and TP53-depleted and AR expressing LNCaP cells.